These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28502767)

  • 1. Modulating angiogenesis with integrin-targeted nanomedicines.
    Duro-Castano A; Gallon E; Decker C; Vicent MJ
    Adv Drug Deliv Rev; 2017 Sep; 119():101-119. PubMed ID: 28502767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrin-mediated drug delivery in cancer and cardiovascular diseases with peptide-functionalized nanoparticles.
    Arosio D; Casagrande C; Manzoni L
    Curr Med Chem; 2012; 19(19):3128-51. PubMed ID: 22612699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
    Arosio D; Manzoni L; Corno C; Perego P
    Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy.
    Rahman M; Akhter S; Ahmad J; Ahmad MZ; Beg S; Ahmad FJ
    Expert Opin Drug Deliv; 2015 Apr; 12(4):635-52. PubMed ID: 25439967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
    Rüegg C; Dormond O; Mariotti A
    Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment.
    David A
    Adv Drug Deliv Rev; 2017 Sep; 119():120-142. PubMed ID: 28506743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deformable Discoidal Polymeric Nanoconstructs for the Precise Delivery of Therapeutic and Imaging Agents.
    Palange AL; Palomba R; Rizzuti IF; Ferreira M; Decuzzi P
    Mol Ther; 2017 Jul; 25(7):1514-1521. PubMed ID: 28341562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancement in integrin facilitated drug delivery.
    Arosio D; Casagrande C
    Adv Drug Deliv Rev; 2016 Feb; 97():111-43. PubMed ID: 26686830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
    Lakshmanan VK
    Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrin targeted drug and gene delivery.
    Wang Z; Chui WK; Ho PC
    Expert Opin Drug Deliv; 2010 Feb; 7(2):159-71. PubMed ID: 20095940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis.
    Lim EH; Danthi N; Bednarski M; Li KC
    Nanomedicine; 2005 Jun; 1(2):110-4. PubMed ID: 17292065
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting.
    Meyer A; Auernheimer J; Modlinger A; Kessler H
    Curr Pharm Des; 2006; 12(22):2723-47. PubMed ID: 16918408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applying nanomedicine in maladaptive inflammation and angiogenesis.
    Alaarg A; Pérez-Medina C; Metselaar JM; Nahrendorf M; Fayad ZA; Storm G; Mulder WJM
    Adv Drug Deliv Rev; 2017 Sep; 119():143-158. PubMed ID: 28506745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymeric nanomedicines as a promising vehicle for solid tumor therapy and targeting.
    Gupta M; Agrawal GP; Vyas SP
    Curr Mol Med; 2013 Jan; 13(1):179-204. PubMed ID: 22834834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicines for kidney diseases.
    Williams RM; Jaimes EA; Heller DA
    Kidney Int; 2016 Oct; 90(4):740-5. PubMed ID: 27292222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered Nanoparticles for Effective Redox Signaling During Angiogenic and Antiangiogenic Therapy.
    Nethi SK; Barui AK; Mukherjee S; Patra CR
    Antioxid Redox Signal; 2019 Feb; 30(5):786-809. PubMed ID: 29943661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
    Muthu MS; Singh S
    Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy.
    Park J; Singha K; Son S; Kim J; Namgung R; Yun CO; Kim WJ
    Cancer Gene Ther; 2012 Nov; 19(11):741-8. PubMed ID: 23018622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.